ストックスクリーナーアプリを入手
49.23
0.26%
-0.13
アフターアワーズ：
49.50
0.27
+0.55%
Bristol Myers Squibb Co (BMY) 最新ニュース
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Bristol Myers (BMY) Gains FDA Nod for Updated Camzyos Label to Simplify Treatment | BMY Stock News - GuruFocus
Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures - TipRanks
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Bristol Myers (BMY) Target Price Trimmed as Revenue Projections Dip | BMY Stock News - GuruFocus
Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now? - Insider Monkey
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Gilead Vs Bristol Myers: Which Biotech Bigwig Is A Better Bet Now? - Barchart.com
Bristol-Myers Squibb (BMY): Potential 19.73% Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Ca - GuruFocus
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis - GuruFocus
Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Bristol Myers stumbles in bid to widen heart drug’s use - BioPharma Dive
BMO maintains Bristol-Myers $61 target after trial setback By Investing.com - Investing.com India
Bristol-Myers stock dips on trial results - Investing.com Australia
BMS’ Camzyos fails to show new cardiomyopathy benefit in Phase III - PharmaLive
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - 01net
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis - Quantisnow
Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? - Insider Monkey
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BMS Phase III Camzyos trial misses endpoints - The Pharma Letter
Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects - TipRanks
Chemotherapy Market Overall Study Report 2025-2032 | - openPR.com
Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos - GuruFocus
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bristol Myers falls as heart disease drug fails in late-stage trial - TradingView
Bristol Myers reports setback in Camzyos heart drug trial - Investing.com
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsight - The Globe and Mail
BMS’ Opdivo combo approved in US for hepatocellular carcinoma - Yahoo Finance
Bristol Myers: new approval for Opdivo+Yervoy - MarketScreener
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week - MedCity News
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit - Medical Dialogues
Bristol Myers Squibb (BMY) Secures FDA Approval for Liver Cancer Treatment - GuruFocus
UBS cuts Bristol-Myers Squibb price target to $54 from $60 By Investing.com - Investing.com South Africa
Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods - insights.citeline.com
Bristol-Myers Squibb Faces Q1 Expectations With Eliquis And Revlimid Leading - Finimize
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? - Insider Monkey
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer - Fierce Pharma
UBS cuts Bristol-Myers Squibb price target to $54 from $60 - Investing.com Australia
Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report - TradingView
Here's What To Expect From Bristol-Myers Squibb's Next Earnings Report - Barchart.com
Dasatinib Drugs Market Deep Research 2025-2032 | Bristol-Myers - openPR.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
10 Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bristol Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises - MarketScreener
FDA Approves Opdivo (BMY) Plus Yervoy Combo for Colorectal Cance - GuruFocus
About us - Bristol Myers Squibb
Bristol Myers Beats Pomalyst Antitrust Suit Alleging IP Fraud - Law360
0.45%
0.32%
大文字化:
|
ボリューム (24 時間):